ATE491467T1 - VACCINE COMPOSITIONS CONTAINING VIROSOMES AND A SAPONIN ADJUVANT - Google Patents

VACCINE COMPOSITIONS CONTAINING VIROSOMES AND A SAPONIN ADJUVANT

Info

Publication number
ATE491467T1
ATE491467T1 AT05747432T AT05747432T ATE491467T1 AT E491467 T1 ATE491467 T1 AT E491467T1 AT 05747432 T AT05747432 T AT 05747432T AT 05747432 T AT05747432 T AT 05747432T AT E491467 T1 ATE491467 T1 AT E491467T1
Authority
AT
Austria
Prior art keywords
compositions containing
vaccine compositions
saponin adjuvant
virosome
provides
Prior art date
Application number
AT05747432T
Other languages
German (de)
Inventor
Beth-Ann Coller
Veronique Henderickx
Nathalie M J Garcon
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35045004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE491467(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0412039.0A external-priority patent/GB0412039D0/en
Priority claimed from GB0412304A external-priority patent/GB0412304D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE491467T1 publication Critical patent/ATE491467T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides virosome preparations from an enveloped virus, in particular from influenza virus, containing an antigen from said virus, and a saponin adjuvant. In particular the invention provides a virosome preparation from influenza virus containing an influenza antigen a QS21, optionally with a sterol. The invention also provides vaccine compositions containing said virosome preparations, methods of preparing said virosome preparations and vaccine containing them.
AT05747432T 2004-05-28 2005-05-26 VACCINE COMPOSITIONS CONTAINING VIROSOMES AND A SAPONIN ADJUVANT ATE491467T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0412039.0A GB0412039D0 (en) 2004-05-28 2004-05-28 Compositions
GB0412304A GB0412304D0 (en) 2004-06-02 2004-06-02 Compositions
PCT/EP2005/005786 WO2005117958A1 (en) 2004-05-28 2005-05-26 Vaccine compositions comprising virosomes and a saponin adjuvant

Publications (1)

Publication Number Publication Date
ATE491467T1 true ATE491467T1 (en) 2011-01-15

Family

ID=35045004

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05747432T ATE491467T1 (en) 2004-05-28 2005-05-26 VACCINE COMPOSITIONS CONTAINING VIROSOMES AND A SAPONIN ADJUVANT

Country Status (8)

Country Link
US (1) US20090263470A1 (en)
EP (2) EP2269638A3 (en)
JP (1) JP2008500984A (en)
AT (1) ATE491467T1 (en)
AU (2) AU2005249212B2 (en)
CA (1) CA2565500A1 (en)
DE (1) DE602005025342D1 (en)
WO (1) WO2005117958A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ568212A (en) * 2005-11-04 2012-03-30 Novartis Vaccines & Diagnostic Changing Th1/Th2 balance in split influenza vaccines with adjuvants
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
TWI457133B (en) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
KR20100045413A (en) * 2007-06-14 2010-05-03 크루셀 스위츨랜드 아게 Intradermal influenza vaccine
EP2058002A1 (en) * 2007-10-31 2009-05-13 Bestewil Holding B.V. Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine
RS53347B (en) 2008-12-09 2014-10-31 Gilead Sciences, Inc. TOLL-SIMILAR RECEPTOR MODULATORS
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP3173097A3 (en) 2009-02-10 2017-07-12 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
JP5854559B2 (en) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド Method for preparing vesicles and preparations produced therefrom
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CA3150411C (en) 2009-07-31 2023-09-12 Pnuvax Inc. High yield yellow fever virus strain with increased propagation in cells
CA2772253C (en) 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
JP5774010B2 (en) * 2009-09-25 2015-09-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunodiffusion assay for influenza virus
JP2013525431A (en) * 2010-04-30 2013-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Use of phospholipid conjugates of synthetic TLR7 agonists
WO2012006367A2 (en) * 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
EP2595653B1 (en) * 2010-07-23 2017-06-28 Novavax AB Influenza vaccine
AR079970A1 (en) * 2010-07-23 2012-02-29 Xcellerex Inc HIGH PERFORMANCE VIRUSES OF THE YELLOW FEVER VIRUS WITH INCREASED PROPAGATION IN THE CELLS
CN102078606B (en) * 2010-12-08 2014-12-31 中国人民解放军军事医学科学院微生物流行病研究所 Respiratory syncytial virosome vaccine and preparation method thereof
CN102107003A (en) * 2011-01-05 2011-06-29 重庆大学 Porcine reproductive and respiratory syndrome Virosome vaccine and preparation method thereof
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTICS
EP4218808A3 (en) * 2012-03-12 2023-08-09 Advanced BioAdjuvants, LLC Adjuvant and vaccine compositions
WO2015000831A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
WO2015000832A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
JP6522732B2 (en) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Modulators of Toll-like receptors for treating HIV
WO2016039620A2 (en) * 2014-09-12 2016-03-17 Bestewil Holding B.V. Respiratory syncytial virus virosomes
WO2016039619A1 (en) * 2014-09-12 2016-03-17 Bestewil Holding B.V. Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby
KR102306860B1 (en) 2014-09-16 2021-09-30 길리애드 사이언시즈, 인코포레이티드 Methods of preparing toll-like receptor modulators
SG11201701520TA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Solid forms of a toll-like receptor modulator
CN104488927A (en) * 2014-12-03 2015-04-08 广东中迅农科股份有限公司 Pesticide composition containing sterol and spirotetramat
BR112018007870A2 (en) 2015-10-19 2019-01-15 Cadila Healthcare Ltd immunogenic composition, method for preparing an immunogenic composition, pharmaceutical composition, vaccine, method for stimulating an immune response in a patient
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
TWI810456B (en) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Combination of a tlr7 modulating compound and an hiv vaccine
CN110302373A (en) * 2019-07-01 2019-10-08 大连民族大学 Oriented arrangement of viral envelope protein vaccine using transmembrane region and preparation method thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
SE8405493D0 (en) 1984-11-01 1984-11-01 Bror Morein IMMUNOGENT COMPLEX AND KITCHEN FOR PREPARING IT AND USING IT AS IMMUNOSTIMENTING AGENTS
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health AUTOCRINE MOBILITY FACTORS IN DIAGNOSTIC AND TREATMENT OF CANCER.
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
PL181241B1 (en) 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Glucosoamine disaccharides, method of obtaining them and pharmaceutical composition containing them as well as their application
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (en) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
WO1998056415A1 (en) 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CA2302522C (en) 1997-08-29 2010-08-17 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
AU7924598A (en) 1998-06-08 1999-12-30 Sca Emballage France Fast flattening packaging
CN1168702C (en) 1998-06-30 2004-09-29 Om药业 Acyl-dipeptide compound, its preparation method and pharmaceutical composition containing the aforementioned compound
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
PT1104306E (en) 1998-08-10 2006-05-31 Antigenics Inc CPG COMPOSITIONS AND SAPONIN ADJUVANTS AND THEIR METHODS
PT1187629E (en) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa ADJUVANT COMPOSITION THAT UNDERSTANDS SAPONIN AND AN IMMUNOSTIMULATOR OLIGONUCLEOTIDE
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
WO2001046127A1 (en) 1999-12-22 2001-06-28 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
KR20050010040A (en) * 2002-06-11 2005-01-26 글락소스미스클라인 바이오로지칼즈 에스.에이. Immunogenic compositions
GB0218921D0 (en) * 2002-08-14 2002-09-25 Glaxosmithkline Biolog Sa Novel vaccine

Also Published As

Publication number Publication date
US20090263470A1 (en) 2009-10-22
CA2565500A1 (en) 2005-12-15
EP2269638A3 (en) 2012-06-13
EP2269638A2 (en) 2011-01-05
DE602005025342D1 (en) 2011-01-27
AU2005249212A1 (en) 2005-12-15
EP1755666B1 (en) 2010-12-15
JP2008500984A (en) 2008-01-17
AU2005249212B2 (en) 2010-05-20
AU2010202974A1 (en) 2010-08-05
EP1755666A1 (en) 2007-02-28
WO2005117958A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
ATE491467T1 (en) VACCINE COMPOSITIONS CONTAINING VIROSOMES AND A SAPONIN ADJUVANT
NO20021431L (en) Intranasal influenza virus vaccine
ATE503493T1 (en) INFLUENZA VACCINE COMPOSITIONS FOR INTRADERMAL ADMINISTRATION
ATE331530T1 (en) PROTEASOME INFLUENZA VIRUS VACCINE COMPOSITION G
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
WO2004112831A3 (en) High titer recombinant influenza viruses for vaccines and gene therapy
WO2007068907A3 (en) Vaccine compositions comprising a saponin adjuvant
EP1326633A4 (en) COMPOSITION COMPRISING IMMUNOGENIC MICROPARTICLES
WO2002087494A3 (en) Novel vaccine
WO2005105139A3 (en) Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy
EP2290091A3 (en) Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
CY1110744T1 (en) Immunosuppressive combination for prophylactic and therapeutic treatment of US C
WO2007052165A3 (en) A lentiviral vector-based vaccine
WO2007052059A3 (en) Changing th1/th2 balance in split influenza vaccines with adjuvants
EA200801251A1 (en) VACCINES AGAINST FLU ADSORBED ON ALUMINUM ADJUVANTS FOR IMMEDIATE ADMISSION
WO2005120564A3 (en) Vaccine compositions and methods
WO2004045641A3 (en) Antigen-complexes
DE60036705D1 (en) ADJUVANSKOMBINATIONS FOR IMMUNIZATION AND VACCINE
WO2007028985A3 (en) Adjuvanted vaccine
ITRM20040066A1 (en) METHOD OF IDENTIFICATION OF ANTIGENIC PEPTIDES AND RELATED USE FOR THE PREPARATION OF AN ANTI HIV-1 VACCINE.
IL193391A0 (en) Influenza antigens, vaccine compositions, and related methods
EP1721618A3 (en) Proteosome influenza vaccine composition
RU2004130267A (en) METHOD FOR VACCINATION OF CHILDREN AGAINST REDDING IN THE EXTREME NORTH
CY1114467T1 (en) MICROWATER OIL-IN-WATER EMULSIONS AND VACCINATION COMPOSITIONS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties